Wed Nov 12 11:06:56 UTC 2025: Okay, here’s a summary and a news article based on the provided text:
Summary:
Despite the initial hype surrounding AI’s potential to revolutionize drug discovery, particularly after Google DeepMind’s AlphaFold breakthrough, the process remains slow and expensive. Eroom’s Law (“Moore’s” spelled backward) highlights the decreasing efficiency in drug discovery per dollar spent, contrasting with Moore’s Law in computing. The core issue is not the quantity of hypotheses generated (which AI has increased exponentially) but the quality. AI excels at pattern recognition in well-defined datasets, but drug discovery is a complex, exploratory process driven by randomness, intuition, and human creativity. While AI can aid in screening, trial design, and drug repurposing, it cannot replace the human element of imagining and discovering new cures. Historically, breakthroughs like penicillin and insulin were accidental discoveries driven by human curiosity and serendipity. Ethical considerations and stringent testing also contribute to the slower pace of drug development. AI can only reshape the territory, and humans must explore.
News Article:
AI’s Promise in Drug Discovery Falls Short of Hype: Human Ingenuity Still Key
New Delhi (November 13, 2025) – Five years after the groundbreaking announcement that Google DeepMind’s AlphaFold had solved the protein-folding problem, the anticipated revolution in drug discovery has yet to materialize. Despite significant investment in artificial intelligence (AI), the development of new cures remains a slow and costly process.
This situation highlights what analysts call “Eroom’s Law,” the inverse of Moore’s Law, indicating a decline in the number of new drugs discovered per billion dollars spent. While AI has exponentially increased the quantity of potential drug candidates, the quality of these hypotheses has not seen a corresponding improvement.
“AI is excellent at identifying patterns within large datasets,” explains Dr. C. Aravinda, a public health physician, “but drug discovery isn’t an examination with predictable questions. It’s exploration in a chaotic environment.”
The article points to historical examples like the accidental discovery of penicillin and insulin as evidence of the role of serendipity and human intuition in medical breakthroughs. Current ethical standards and rigorous testing procedures also contribute to the slower pace of drug development.
While AI will undoubtedly play a role in areas like screening, clinical trial design, and repurposing existing drugs, experts caution against expecting AI to independently create new cures. “AI can only reshape knowledge faster. It cannot imagine or create it, ” notes the article. The human mind, with its capacity for creativity and a willingness to explore beyond the data, remains essential in the ongoing quest for medical advancements.
First Piper 